More PRNewswire
View Older Stories View Newer Stories-
Global Times: China enhances village inspection to crack down on corruption at grassroot level as anti-graft campaign enters uncharted water
-
Researchers Highlight Urgent Need for Land Restoration and Food System Reforms to Protect Climate and Biodiversity
-
Gentari to supply large-scale, carbon-free energy to AMG Ammonia
-
Northern Data Group presents AI-enabled film "The Glass Hermit" by Oscar-winner Shona Heath
-
TrinaTracker unlocks its SuperTrack potential, with annual power generation increased 2% to 4%
-
Skanska signs contract for the next part of NKT's cable factory in Karlskrona, Sweden, worth about SEK 1.2 billion
-
Boliden to acquire the Neves-Corvo and Zinkgruvan mines
-
$300 Billion in Estimated Annual Consumer Harm Linked to Fake Reviews, Transparency Company Research Report Reveals
-
AGC to Exhibit at CES 2025: Showcasing Cutting-edge Materials and Solutions, Including World Premieres
-
Ellucian Partners with Naseej for Technology to Accelerate Higher Education Transformation in Saudi Arabia
-
Education Cannot Wait High-Level Mission in Ethiopia Calls for Bold Innovative Financing Solutions to Urgently Address the Education Needs of 9 Million Crisis-Affected Out-of-School Children
-
Desert Control Secures Agreement with Woodland Hills Country Club for Deployment of Water Conservation Technology
-
Moomoo's Inaugural Global Paper Trading Challenge Concludes with Over 150,000 Participants and Incredible Performance
-
Sovereign Wealth and Public Pension Funds Set to Reshape Private Markets
-
Geopolitics and Generative AI: Will Middle Powers Reshape the Map?
-
Group Elephant business Valcann named Latin America's 'AWS Collaboration Partner of the Year'
-
LG released new version of generative AI, EXAONE 3.5
-
AnX Robotica awarded Gastrointestinal Endoscopy Products agreement with Premier, Inc.
-
Taiwan's Products for Modern Households Focus on Customization, Health, and Wellbeing
-
BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL
-
Global Times: Doctor and warrior: Chinese MMA fighter Shi Ming rises to fame for contrasting identities
-
WSPN Partners with Fractal to Expand Stablecoin Access on Bitcoin
-
The revival of Notre-Dame witnesses the value of cultural exchange and mutual learning: Global Times editorial
-
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
-
At Harvard Symposium, Squirrel Ai's Dr. Joleen Liang Forecasts the Next Chapter in AI-Driven Education
-
Global Total Semiconductor Equipment Sales Forecast to Reach a Record of $139 Billion in 2026, SEMI Reports
-
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagn
-
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
-
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
-
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-
SK Life Science, Inc. Presents XCOPRI® (cenobamate tablets) CV Data at the AES 2024 Annual Meeting Showing a Deeper Understanding of Cenobamate's Dual Mechanism of Action
-
WTCH 24 - Countless historical results and a new superpower emerged
-
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
-
Apple Sued for Knowingly Hosting Child Sexual Abuse Material on Its Products, Failing to Protect Survivors
-
Global Times: People's Daily article says favorable conditions for China's economic development remain unchanged
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
-
Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions
-
Max Stock Limited: Immediate report of changes to interested party holdings
-
National Press Club: Family Of Austin Tice Available for Interviews at St. John's Church
-
Nanning: A Colorful City of Cultural Diversity
-
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
-
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
-
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
-
PRIME MINISTER OF MONGOLIA MAKES HISTORIC VISIT TO MIDDLE EAST
-
Global Times: Clay Figure Zhang's works naturally reflect spiritual state of the times
-
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
-
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
